Article Information
History
- January 5, 2022.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Vivek Naranbhai1,2,3,†,*,#,
- Anusha Nathan4,5,†,
- Clarety Kaseke4,
- Cristhian Berrios6,
- Ashok Khatri7,
- Shawn Choi7,
- Matthew A. Getz4,
- Rhoda Tano-Menka4,
- Onosereme Ofoman6,
- Alton Gayton4,
- Fernando Senjobe4,
- Kerri J. St Denis4,
- Evan C. Lam4,
- Wilfredo F. Garcia-Beltran4,6,
- Alejandro B. Balazs4,
- Bruce D. Walker3,4,8,9,10,
- A. John Iafrate6 and
- Gaurav D. Gaiha4,11,*,#
- 1Massachusetts General Hospital Cancer Center, Massachusetts General Hospital, Boston, MA 02114, USA
- 2Dana-Farber Cancer Institute, Boston, MA 02215, USA
- 3Center for the AIDS Programme of Research in South Africa, Durban 4001, South Africa
- 4Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA
- 5Program in Health Sciences & Technology, Harvard Medical School & Massachusetts Institute of Technology, Boston, MA 02115, USA
- 6Department of Pathology, Massachusetts General Hospital, Boston, MA 02114, USA
- 7Massachusetts General Hospital Endocrine Division and Department of Medicine, Harvard Medical School, Boston, MA 02114, USA
- 8The Broad Institute, Cambridge, MA 02142, USA
- 9Howard Hughes Medical Institute, Chevy Chase, MD 20815, USA
- 10Institute for Medical Engineering and Science and Department of Biology, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
- 11Division of Gastroenterology, Massachusetts General Hospital, Boston, MA 02114, USA
- ↵#Correspondence: vnaranbhai{at}mgh.harvard.edu (V.N.), ggaiha{at}mgh.harvard.edu (G.D.G)
Posted January 05, 2022.
T cell reactivity to the SARS-CoV-2 Omicron variant is preserved in most but not all prior infected and vaccinated individuals
